High prevalence of TP53 mutations is associated with poor survival and epithelial-mesenchymal transition signature in gliosarcoma patients

Gliosarcoma (GS) is a rare variant (2%) of glioblastoma (GBM) and poses clinical genomic challenges because of poor prognosis and limited genomic information1-3. To understand the molecular etiology of GS, we applied whole-exome sequencing for 28 GS cases from different patient cohorts. Mutations of TP53 were more predominantly prevalent in GS cases (70% (20/28)) compared to GBM cases (32% (29/90)), and GS patients with TP53 mutations showed a significantly shorter survival (P = 0.019).